

# CITATION REPORT

List of articles citing

**B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity**

**DOI: 10.1128/iai.67.9.4862-4869.1999**

**Infection and Immunity, 1999, 67, 4862-9.**

**Source:** <https://exaly.com/paper-pdf/30032228/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
81	Current World Literature. <i>Current Opinion in Infectious Diseases</i> , <b>2000</b> , 13, 277-332	5.4	
80	Nouvelles cibles pour les vaccins antibactériens. <i>Revue Francaise Des Laboratoires</i> , <b>2000</b> , 2000, 53-60		
79	CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. <i>Infection and Immunity</i> , <b>2000</b> , 68, 1450-6	3.7	75
78	The ability of B cells and dendritic cells to present antigen increases during ontogeny. <i>Journal of Immunology</i> , <b>2000</b> , 165, 4803-13	5.3	77
77	Serotype of <i>Streptococcus pneumoniae</i> capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococcal-CRM(197) conjugate vaccines in a murine model. <i>Vaccine</i> , <b>2000</b> , 19, 1159-66	4.1	42
76	Exploiting molecular mimicry to broaden the immune response to carbohydrate antigens for vaccine development. <i>Vaccine</i> , <b>2001</b> , 19, 2361-8	4.1	17
75	Novel vaccine strategies to T-independent antigens. <i>Journal of Microbiological Methods</i> , <b>2001</b> , 47, 135-49.8	4.8	100
74	Dimensions of antigen recognition and levels of immunological specificity. <i>Advances in Cancer Research</i> , <b>2001</b> , 80, 147-87	5.9	24
73	Current concepts in cancer vaccine strategies. <i>BioTechniques</i> , <b>2001</b> , 30, 170-2, 174, 176 passim	2.5	22
72	Human monoclonal antibodies against <i>Pseudomonas aeruginosa</i> lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal <i>pseudomonas</i> sepsis. <i>Infection and Immunity</i> , <b>2001</b> , 69, 2223-9	3.7	44
71	Directing the immune response to carbohydrate antigens. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 30490-8	5.4	29
70	Immunization with <i>Haemophilus influenzae</i> type b-CRM(197) conjugate vaccine elicits a mixed Th1 and Th2 CD(4+) T cell cytokine response that correlates with the isotype of antipolysaccharide antibody. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 184, 931-5	7	41
69	Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1. <i>Journal of Immunology</i> , <b>2002</b> , 168, 3437-43	5.3	55
68	Enhanced immunogenicity of pneumococcal surface adhesin A by genetic fusion to cytokines and evaluation of protective immunity in mice. <i>Infection and Immunity</i> , <b>2002</b> , 70, 5589-95	3.7	33
67	<i>Streptococcus pneumoniae</i> polysaccharides conjugated to the outer membrane protein A from <i>Klebsiella pneumoniae</i> elicit protective antibodies. <i>Vaccine</i> , <b>2002</b> , 20, 2174-80	4.1	18
66	Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery. <i>Trends in Biotechnology</i> , <b>2002</b> , 20, 207-14	15.1	75
65	Current state of pneumococcal vaccines. <i>Scandinavian Journal of Immunology</i> , <b>2002</b> , 56, 111-29	3.4	48

64	Modulation of the T cell response to beta-lactoglobulin by conjugation with carboxymethyl dextran. <i>Bioconjugate Chemistry</i> , <b>2003</b> , 14, 168-76	6.3	20
63	Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 187, 1629-38	7	59
62	Antigen processing of the heptavalent pneumococcal conjugate vaccine carrier protein CRM(197) differs depending on the serotype of the attached polysaccharide. <i>Infection and Immunity</i> , <b>2003</b> , 71, 4186-9	2.7	21
61	Genetic variation influences the B-cell response to immunization with a pneumococcal polysaccharide conjugate vaccine. <i>Infection and Immunity</i> , <b>2003</b> , 71, 5402-6	3.7	8
60	Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. <i>Infection and Immunity</i> , <b>2004</b> , 72, 5807-13	3.7	137
59	A murine model for the study of immune memory in response to pneumococcal conjugate vaccination. <i>Vaccine</i> , <b>2004</b> , 22, 3069-79	4.1	9
58	Intratracheal and intranasal immunization with ovalbumin conjugated with Bacillus firmus as a carrier in mice. <i>Folia Microbiologica</i> , <b>2005</b> , 50, 247-53	2.8	4
57	Carbohydrate mimotopes in the rational design of cancer vaccines. <i>Current Topics in Medicinal Chemistry</i> , <b>2005</b> , 5, 1171-85	3	12
56	Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. <i>Infection and Immunity</i> , <b>2005</b> , 73, 1304-12	3.7	64
55	Reduced T cell response to beta-lactoglobulin by conjugation with acidic oligosaccharides. <i>Journal of Agricultural and Food Chemistry</i> , <b>2005</b> , 53, 6851-7	5.7	12
54	Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine. <i>International Journal of Molecular Medicine</i> , <b>2006</b> , 17, 1045	4.4	
53	Early life T cell responses to pneumococcal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy. <i>European Journal of Immunology</i> , <b>2006</b> , 36, 287-95	6.1	26
52	Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice. <i>Infection and Immunity</i> , <b>2007</b> , 75, 1643-50	3.7	23
51	Immunogenicity of bioactive magnetic nanoparticles: natural and acquired antibodies. <i>Journal of Biomedical Materials Research - Part A</i> , <b>2008</b> , 85, 1011-21	5.4	35
50	The role of complement in the success of vaccination with conjugated vs. unconjugated polysaccharide antigen. <i>Vaccine</i> , <b>2008</b> , 26, 451-9	4.1	11
49	Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. <i>Vaccine Journal</i> , <b>2008</b> , 15, 182-93		45
48	Pattern of functional antibody activity against Haemophilus influenzae type B (Hib) in infants immunized with diphtheria-tetanus-pertussis/Hib Brazilian combination vaccine. <i>Brazilian Journal of Medical and Biological Research</i> , <b>2009</b> , 42, 1242-7	2.8	7
47	Design, synthesis, and immunochemical characterization of a chimeric glycopeptide corresponding to the Shigella flexneri Y O-polysaccharide and its peptide mimic MDWNMHAA. <i>Carbohydrate Research</i> , <b>2009</b> , 344, 1412-27	2.9	9

46	Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PS A1 conjugates. <i>Journal of the American Chemical Society</i> , <b>2009</b> , 131, 9622-3	16.4	91
45	Immune surveillance and immunotherapy: lessons from carbohydrate mimotopes. <i>Vaccine</i> , <b>2009</b> , 27, 3405-15	4.1	23
44	2009 Claude S. Hudson Award in Carbohydrate Chemistry. Carbohydrates: a frontier in medicinal chemistry. <i>Journal of Medicinal Chemistry</i> , <b>2009</b> , 52, 5561-77	8.3	124
43	Discovery and design of carbohydrate-based therapeutics. <i>Expert Opinion on Drug Discovery</i> , <b>2010</b> , 5, 721-37	6.2	48
42	Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 1174-83	11.6	26
41	Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance. <i>Vaccine</i> , <b>2010</b> , 28, 1333-40	4.1	29
40	Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. <i>Vaccine</i> , <b>2010</b> , 28, 3341-9	4.1	64
39	Outer membrane protein complex of Meningococcus enhances the antipolysaccharide antibody response to pneumococcal polysaccharide-CRM $\alpha$ conjugate vaccine. <i>Vaccine Journal</i> , <b>2011</b> , 18, 724-9		8
38	Glycan mediated immune responses to tumor cells. <i>Hum Vaccin</i> , <b>2011</b> , 7 Suppl, 156-65		12
37	Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 130, S1-24	11.5	276
36	Carbohydrate-based cancer vaccines: target cancer with sugar bullets. <i>Glycoconjugate Journal</i> , <b>2012</b> , 29, 259-71	3	47
35	Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. <b>2013</b> , 504-541		7
34	Th17 cell based vaccines in mucosal immunity. <i>Current Opinion in Immunology</i> , <b>2013</b> , 25, 373-80	7.8	62
33	. <b>2014</b> ,		4
32	Immunity in the first year of life and call for vaccination. <i>International Journal of Biological Research</i> , <b>2014</b> , 2,	0	
31	The relevance of pneumococcal serotypes. <i>Current Infectious Disease Reports</i> , <b>2014</b> , 16, 403	3.9	12
30	Conjugate Vaccine Production Technology. <b>2014</b> , 217-235		3
29	Human Infant Memory B Cell and CD4+ T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine. <i>PLoS ONE</i> , <b>2015</b> , 10, e0133126	3.7	3

28	A Self-Assembling Peptide Scaffold for the Multivalent Presentation of Antigens. <i>Biomacromolecules</i> , <b>2015</b> , 16, 2188-97	6.9	21
27	Conjugation of $\beta$ -glucan markedly increase the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine. <i>Vaccine</i> , <b>2015</b> , 33, 2066-72	4.1	10
26	Molecular shape and immunogenicity of meningococcal polysaccharide group A conjugate vaccine. <i>Vaccine</i> , <b>2015</b> , 33, 5815-5821	4.1	8
25	Fully Synthetic Self-Adjuvanting $\beta$ -D-9-Oligosialic Acid Based Conjugate Vaccines against Group C Meningitis. <i>ACS Central Science</i> , <b>2016</b> , 2, 210-8	16.8	52
24	Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain. <i>Vaccine</i> , <b>2017</b> , 35, 865-872	4.1	13
23	Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model. <i>Human Vaccines and Immunotherapeutics</i> , <b>2017</b> , 13, 1169-1176	4.4	5
22	Effect of protein immunogenicity and PEG size and branching on the anti-PEG immune response to PEGylated proteins. <i>Process Biochemistry</i> , <b>2017</b> , 52, 183-191	4.8	31
21	Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines. <b>2018</b> , 773-815.e18		6
20	Design and Biological Assembly of Polyester Beads Displaying Pneumococcal Antigens as Particulate Vaccine. <i>ACS Biomaterials Science and Engineering</i> , <b>2018</b> , 4, 3413-3424	5.5	12
19	Preclinical Assessment of Glycoconjugate Vaccines. <i>ACS Symposium Series</i> , <b>2018</b> , 229-247	0.4	1
18	Immunogenicity and protective efficacy of monovalent PCVs containing 22F and 33F polysaccharides in mouse models of colonization and co-infection. <i>Vaccine</i> , <b>2018</b> , 36, 5701-5708	4.1	2
17	Complementary Role of CD4+ T Cells in Response to Pneumococcal Polysaccharide Vaccines in Humans. <i>Vaccines</i> , <b>2019</b> , 7,	5.3	10
16	Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2695	8.4	1
15	Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants. <i>Pediatric Infectious Disease Journal</i> , <b>2020</b> , 39, 70-77	3.4	7
14	Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. <i>Advanced Drug Delivery Reviews</i> , <b>2020</b> , 154-155, 163-175	18.5	103
13	Elicitation of integrated immunity in mice by a novel pneumococcal polysaccharide vaccine conjugated with HBV surface antigen. <i>Scientific Reports</i> , <b>2020</b> , 10, 6470	4.9	3
12	Booster immunization with a fractional dose of Prevnar 13 affects cell-mediated immune response but not humoral immunity in CD-1 mice. <i>Heliyon</i> , <b>2021</b> , 7, e07314	3.6	
11	Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. <i>Vaccine</i> , <b>2021</b> , 39, 4231-4237	4.1	3

10	Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. <b>2008</b> , 531-567		6
9	The Immunobiology of Polysaccharide and Conjugate Vaccines. 67-82		5
8	Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006250	7.6	56
7	Exploiting Molecular Mimicry in Targeting Carbohydrate Antigens. 175-196		
6	PROTEINS AND OTHER CARRIERS FOR CREATION OF CONJUGATED VACCINES: PROPERTIES AND APPLICATION. <i>Zhurnal Mikrobiologii Epidemiologii I Immunobiologii</i> , <b>2016</b> , 115-124	0.5	
5	Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.. <i>Npj Vaccines</i> , <b>2022</b> , 7, 12	9.5	1
4	Image_1.TIF. <b>2019</b> ,		
3	A prospective study of the infant gut microbiome in relation to vaccine response. <i>Pediatric Research</i> , <b>2022</b> ,	3.2	
2	Pneumococcal conjugate vaccine does not induce humoral response when administrated within the six months after CD19 CAR T cell therapy. <b>2022</b> ,		1
1	Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults.		0